arrow
C

Charlotte Beaudart

who collaborating centre for epidemiology of musculoskeletal health and aging
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Single-component imaging and ultrasound-based tools for the assessment of fracture risk

单组分成像和超声基工具在骨折风险评估中的应用

2026-10-010
PRE
Health-related quality of life instruments for older persons with osteoporosis: a WHO-BOHEG systematic review of measurement properties for use in clinical trials and routine practice

骨质疏松老年患者健康相关生活质量量表:WHO-BOHEG关于测量属性的系统评价,用于临床试验和常规实践

2026-05-010
PRE
Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX

更正:BMD对髋部及其他骨折的预测价值:一项用于更新FRAX的荟萃分析

2026-04-010
PRE
Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX

股骨颈和其他骨折的BMD预测价值:一项更新FRAX的Meta分析

2026-03-120
PRE
A meta-analysis of smoking and fracture risk to update the FRAX® tool

吸烟与骨折风险的Meta分析,以更新FRAX®工具

2026-03-040
PRE
Psychometric Properties of the SarQoL Questionnaire: A Systematic Review and Meta-Analysis

SarQoL问卷的心理测量属性:一项系统评价和Meta分析

2025-12-010
OAAI
Author Correction: Parathyroid hormone receptor agonists in the management of osteoporosis

作者更正:甲状旁腺激素受体激动剂在骨质疏松症管理中的应用

2025-09-300
OAAI
Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool

骨折家族史与骨折风险:一项更新FRAX®风险评估工具的荟萃分析

2025-08-230
PRE
Barriers and solutions for global access to osteoporosis management: a Position Paper from the International Osteoporosis Foundation

全球骨质疏松症管理获取的障碍与解决方案:国际骨质疏松基金会立场文件

2025-08-220
OAAI
Towards a core outcome set for sarcopenia intervention studies: a scoping review identifying the most frequently reported outcomes across randomized controlled trials in sarcopenia

关于制定肌肉减少症干预研究核心结局指标集:一项识别肌肉减少症随机对照试验中报告频率最高的结局指标的范畴综述

2025-08-120
OAAI
Parathyroid hormone receptor agonists in the management of osteoporosis

甲状旁腺激素受体激动剂在骨质疏松症管理中的应用

2025-08-110
PRE